Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128068 | 1.00 | CYP3A4 (0.47) | CYP3A4EPHX2NR1H4PDPK1PTGS2 | |
| SCHEMBL2128070 | 1.00 | CYP3A4 (0.47) | CYP3A4EPHX2NR1H4PDPK1PTGS2 | |
| SCHEMBL2127415 | 0.85 | CYP3A4 (0.62) | CYP3A4EPHX2NR1H4PDPK1NR3C2 | |
| SCHEMBL1542584 | 0.85 | CYP3A4 (0.62) | CYP3A4EPHX2NR1H4PDPK1NR3C2 | |
| SCHEMBL2127133 | 0.80 | CYP3A4 (0.48) | CYP3A4PDPK1TRPV1BRD4EP300 | |
| SCHEMBL2127134 | 0.80 | CYP3A4 (0.48) | CYP3A4PDPK1TRPV1BRD4EP300 | |
| SCHEMBL2127652 | 0.79 | CYP3A4 (0.74) | CYP3A4EPHX2NR1H4PDPK1PTGS2 | |
| SCHEMBL2127662 | 0.79 | CYP3A4 (0.74) | CYP3A4EPHX2NR1H4PDPK1PTGS2 | |
| SCHEMBL2127657 | 0.79 | CYP3A4 (0.74) | CYP3A4EPHX2NR1H4PDPK1PTGS2 | |
| SCHEMBL1542324 | 0.77 | CYP3A4 (0.62) | CYP3A4EPHX2NR1H4TRPV1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885EPHX2 3098/4885NR1H4 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.